Epimmune Inc.

Cytel Corporation

Pharmexa Inc.

Ralph T Kubo

Esteban Celis

Alessandro D Sette

Howard M Grey

John Sidney

Scott Southwood

Robert W Chesnut

Brian D Livingston

Maria A Vitiello

Denise Marie Baker

Robert W Chestnut

W Martin Kast

Horacio Serra

Van Tsai

Peggy Wentworth

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. One such peptide, NMLSTVLGV (SEQ ID NO: 183) is useful to elicit an immune response against influenza. The present invention also provides a heteropolymer of an isolated immunogenic peptide less than 15 amino acids in length comprising the oligopeptide NMLSTVLGV (SEQ ID NO: 183) and at least one different peptide.

HLA binding motifs and peptides and their uses

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepareepitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.

[object Object]

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

Inducing cellular immune responses to hepatitis B virus using peptide compositions

Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions

Methods for making peptides comprising an HLA-A24.1-, HLA-A1-, HLA-A11-, and HLA-A3.2-restricted T cell epitope consisting of about 8-11 amino acid residues, and methods of making a peptide that binds to an HLA-A24.1, HLA-A1, HLA-A11, and HLA-A3.2 molecule at a dissociation constant of less than 500 nM.

Methods for making HLA binding peptides and their uses

Methods for activating cytotoxic T lymphocytes (CTL) in vitro are presented in conjunction with methods for using the activated CTL for therapy in vivo. Additionally, a method for killing specific CTL in vivo is presented using antigen presenting cells which were modified in vitro.

Methods for ex vivo therapy using peptide-loaded antigen presenting

The present invention relates to compositions and methods for treating cancer. The invention provides peptides based on a 9 residue epitope derived from the product of the tumor-associated gene MAGE-3. The peptide induces CTL that kill melanoma and other tumor cells lines.

Induction of anti-tumor cytotoxic T lymphocytes in humans using

Growing community of inventors

Carlsbad, CA, United States of America

Ralph T Kubo